Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PT Jayamas Medica Industri Tbk (OMED.JK)
Sidoarjo, ID
Operating under its OneMed brand, PT Jayamas Medica Industri Tbk specializes in the production and distribution of a diverse array of medical devices and supplies. The company's reach extends across Indonesia, Asia, the United States, South America, and Africa. Its business operations are structured into three primary segments: manufacturing, distribution, and retail. The extensive product portfolio includes a comprehensive selection of disposable and consumable medical items, such as syringes, gauze, plaster bandages, masks, medical gloves, urine bags, foley catheters, and alcoholic tissues. Additionally, it provides various antiseptic and disinfectant solutions, including povidone iodine, medical alcohol, and blood cleansing liquids like Hdsol. Diagnostic instruments and equipment form another key category, offering everything from patient monitors, vital signs monitors, and ECG readers to syringe pumps, infusion pumps, tensimeters, and oxymeters. For mobility and rehabilitation, the company supplies products like wheelchairs, crutches, and walkers. Its biotechnology and laboratory offerings encompass pregnancy tests, PCR tests, blood collection tubes, PCT tubes, and chemical reagents. Rounding out its inventory are hospital furnishings, such as patient beds, bedside cabinets, pediatric patient beds, and surgical lamps, alongside other general consumer medical products. These essential medical goods are distributed and retailed through the company's network of Medicom stores and various digital platforms. PT Jayamas Medica Industri Tbk was founded in Sidoarjo, Indonesia, in 2000 and functions as a subsidiary of Pt. Intisumber Hasilsempurna.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +13.86% | -5.74% | -20.14% | -8.00% | +15.00% | +10.58% | +31.43% | +17.35% | -8.73% | -8.73% | -8.73% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+9.4% ★ Q1'26: +31.2% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+14.1% Q1'26: +35.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+13.7% Q1'26: +5.4% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+18.7% ★ Q1'26: +19.2% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+19.3% ★ Q1'26: +19.5% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%-0.1% ★ Q1'26: -0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.47× ★ Q1'26: 0.52× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
1.74T
est: 1.70T (+2.4%)
|
1.89T
est: 1.77T (+6.3%)
|
2.06T
est: 2.05T (+0.6%)
|
2.40T
2.38T – 2.41T
+16.7% YoY
|
2.73T
2.67T – 2.79T
+13.9% YoY
|
3.08T
3.01T – 3.15T
+12.9% YoY
|
| EBITDA |
370.67B
est: 497.13B (-25.4%)
|
433.68B
est: 443.16B (-2.1%)
|
457.37B
est: 512.60B (-10.8%)
|
598.28B
595.15B – 601.42B
+16.7% YoY
|
681.47B
666.01B – 696.93B
+13.9% YoY
|
769.40B
751.23B – 787.57B
+12.9% YoY
|
| EBIT |
344.86B
est: 480.81B (-28.3%)
|
413.61B
est: 414.47B (-0.2%)
|
386.38B
est: 479.42B (-19.4%)
|
559.55B
556.62B – 562.49B
+16.7% YoY
|
637.35B
622.90B – 651.81B
+13.9% YoY
|
719.59B
702.60B – 736.59B
+12.9% YoY
|
| Net Income |
259.36B
est: 224.59B (+15.5%)
|
321.67B
est: 273.11B (+17.8%)
|
366.95B
est: 335.31B (+9.4%)
|
406.50B
405.67B – 454.23B
+21.2% YoY
|
465.50B
463.53B – 520.76B
+14.5% YoY
|
529.00B
527.67B – 602.64B
+13.6% YoY
|
| SGA |
103.75B
est: 80.61B (+28.7%)
|
108.47B
est: 120.74B (-10.2%)
|
302.95B
est: 139.66B (+116.9%)
|
163.01B
162.15B – 163.86B
+16.7% YoY
|
185.67B
181.46B – 189.88B
+13.9% YoY
|
209.63B
204.68B – 214.58B
+12.9% YoY
|
| EPS |
9.59
est: 8.30 (+15.5%)
|
11.89
est: 10.10 (+17.7%)
|
13.57
est: 12.40 (+9.4%)
|
15.90
15.00 – 16.80
+28.2% YoY
|
18.20
17.14 – 19.26
+14.5% YoY
|
20.90
19.51 – 22.29
+14.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-25 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-13 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-12 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-05 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-04 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-15 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Daniel Kurniawan | Corporate Secretary | — | male |
| Eka Suwignyoo | Director of Finance & Director | — | male |
| Herlien Sri Ariani | President Director | — | — |
| Leonard Hariadi Hartanto | Director of Operations & Director | — | male |
| Louis Krisnadi Hartanto | Marketing & Sales Director and Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OMED.JK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
